Since late 1980s, porcine reproductive and respiratory syndrome virus (PRRSV) has emerged as the most economically important swine pathogen affecting pig industries worldwide. Vaccination is the principal means that have been used for prevention of PRRSV infection. However, the currently available vaccines for PRRSV are generally considered as not very effective. One of the major obstacles for developing an effective modified live-attenuated vaccine (MLV) with broad protection is the delayed and insufficient immune responses mounted by PRRSV, and the problem is further exacerbated by the antigenic variations of the constantly-evolving field strains of PRRSV.

In order to boost the immune response induced by the MLV vaccine virus, we evaluated the immunogenicity and vaccine efficacy of recombinant PRRSV MLVs expressing porcine IL-15 or IL-18 as adjuvants. The cytokine genes were fused with a GPI modification signal so that they are anchored onto the cell surface upon infection with the recombinant MLV. Both cytokines are successfully expressed on the cell membrane of porcine alveolar macrophage (PAMs) after recombinant MLVs infection in vitro. Subsequently, pigs vaccinated with cytokine-expressing recombinant PRRSV MLVs had an improved antiviral response of cytotoxic lymphocytes including natural killer (NK) cells and T cells, characterized by increased IFN-γ secretion and/or enhanced CD107a expression. The results offer a novel strategy to incorporate cytokine genes into PRRSV genome as potent bio-active adjuvants expressed by the vaccine virus itself.

Since we showed that PRRSV VR2385 down-regulated swine leukocyte antigen class I surface expression, naturally the next logical question is which viral protein is responsible for this down-regulation. To answer the question, we cloned and expressed all known PRRSV structural and non-structural proteins and examined which protein(s) is involved in SLA-I downregulation. Our results identified the newly-discovered nonstructural protein Nsp2TF of PRRSV as the main mediator in down-regulating SLA-I expression. We also demonstrated that the Nsp2TF-knockout mutant virus lost its function of negatively modulating SLA-I presentation compared to the wild-type virus. The results suggest that disruption of the Nsp2TF's ability to down-regulate SLA-I expression may improve the existing PRRSV vaccines towards a better CMI response against the virus.